To provide glaucoma specialists and comprehensive ophthalmologists with up-to-date information on the treatment and management of patients with glaucoma.
This activity is designed for glaucoma specialists and comprehensive ophthalmologists. No prerequisites required.
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity. At the conclusion of this activity, the participant should be able to:
- Assess patients at risk for developing glaucoma and detect the disease in its
- Express the importance of patient compliance with glaucoma treatment, and provide ophthalmologists with practical strategies to improve compliance.
- Identify how industry and organized medicine can work together to improve patient care.
- Discuss current and emerging medical therapies in the management of glaucoma.
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The estimated time to complete this educational activity: 2 hours.
Release date: April 15, 2007. Expiration date: April 15, 2009.
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
This program is supported by an educational grant from Pfizer, Inc.